Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Chubb
Colorcon
AstraZeneca
QuintilesIMS
Johnson and Johnson
Cipla
UBS
US Army
Healthtrust

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,687,075

« Back to Dashboard

Which drugs does patent 7,687,075 protect, and when does it expire?


Patent 7,687,075 protects OSMOPREP and is included in one NDA. There has been one Paragraph IV challenge on Osmoprep.

This patent has twenty-eight patent family members in eleven countries.

Summary for Patent: 7,687,075

Title:Colonic purgative composition with soluble binding agent
Abstract:This invention relates to novel colonic purgative compositions in a solid dosage form, comprising at least one purgative and at least one soluble, or soluble, nonfermentable binder, such as polyethylene glycol. Further, this invention relates to methods of using the colonic purgative compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time improving the quality of bowel cleansing. The formulations and methods of this invention are particularly useful to cleanse the bowel prior to diagnostic and surgical procedures and can also be employed in lower dosages as a laxative to promote elimination and/or to relieve constipation.
Inventor(s): Skiendzielewski; Stephen (Norristown, PA), Rose; Martin (Bethesda, MD), Do; Ngoc (Bel Air, MD)
Assignee: Salix Pharmaceuticals, Ltd. (Morrisville, NC)
Application Number:10/988,693
Patent Claim Types:
see list of patent claims
Formulation; Dosage form; Composition; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Salix Pharms
OSMOPREP
sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
TABLET;ORAL021892-001Mar 16, 2006RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,687,075

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,718,197Colonic purgative composition with soluble binding agent► Subscribe
8,507,009Colonic purgative composition with soluble binding agent► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,687,075

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina046651► Subscribe
Australia2004292428► Subscribe
Australia2011202346► Subscribe
Australia2012202628► Subscribe
Australia2012216409► Subscribe
Australia2015221520► Subscribe
Brazil122014001142► Subscribe
BrazilPI0416702► Subscribe
Canada2546637► Subscribe
Canada2814523► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Argus Health
UBS
Boehringer Ingelheim
Express Scripts
Novartis
Daiichi Sankyo
Fish and Richardson
Julphar
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot